Activyl

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

indoksakarb

Available from:

Intervet International BV

ATC code:

QP53AX27

INN (International Name):

indoxacarb

Therapeutic group:

Dogs; Cats

Therapeutic area:

Ectoparasiticides za vanjsku primjenu, uključujući. insekticidi, indoxacarb

Therapeutic indications:

Liječenje i prevencija zaraze buha. Za pse i mačke: Liječenje i prevencija zaraze buha. Veterinarski medicinski proizvod može se koristiti kao dio strategije liječenja alergije dermatitisa buha. Razvijanje stadija buha u neposrednom okruženju kućnih ljubimaca ubijeno je nakon kontakta s kućnim ljubimcima tretiranim s Activylom.

Product summary:

Revision: 8

Authorization status:

odobren

Authorization date:

2011-02-18

Patient Information leaflet

                                27
B. UPUTA O VMP
28
UPUTA O VMP
ACTIVYL SPOT-ON OTOPINA ZA PSE
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
PROIZVODNE SERIJE, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet:
Intervet International BV
Wim de Korverstraat 35
5831 AN Boxmeer
Nizozemska
Nositelj odobrenja za proizvodnju za puštanje proizvodne serije:
Intervet Proizvodnja S.A.
Rue de Lyons
27460 Igoville
France
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Activyl 100 mg spot on otopina za jako male pse
Activyl 150 mg spot on otopina za male pse
Activyl 300 mg spot on otopina za srednje pse
Activyl 600 mg spot on otopina za velike pse
Activyl 900 mg spot on otopine za iznimno velike pse
indoksakarb
3.
NAVOĐENJE DJELATNE(IH) TVARI I DRUGIH SASTOJAKA
DJELATNE TVARI:
Jedan ml sadržava 195 mg indoksakarba.
Jedna pipeta Activyl sadrži:
DOZA (ML)
INDOKSAKARB (MG)
Activyl za jako male pse (1,5 - 6,5 kg)
0,51
100
Activyl za male pse (6,6 - 10 kg)
0,77
150
Activyl za srednje pse (10,1 - 20 kg)
1,54
300
Avtivyl za velike pse (20,1 - 40 kg)
3,08
600
Activyl za iznimno velike pse (40,1 – 60 kg)
4,62
900
Također sadrži izopropilni alkohol 354 mg/ml.
Bistra, bezbojna do žuta otopina.
4.
INDIKACIJE
Liječenje i sprečavanje infestacije buha (
_Ctenocephalides felis_
). Učinkovitost protiv novih infestacija
buhama traje 4 tjedna nakon jedne primjene.
29
Ubija razvojne stadije buha koje se nalaze u neposrednoj blizini
ljubimca tretiranog Activylom.
5.
KONTRAINDIKACIJE
Nema.
6.
NUSPOJAVE
U vrlo rijetkim slučajevima može doći do razdoblja povećanog
slinjenja ako životinja liže mjesto
aplikacije odmah nakon tretmana. To nije znak intoksikacije i nestaje
u roku od nekoliko minuta bez
liječenja. Ispravna primjena (vidi odjeljak 4.9) će smanjiti lizanje
na mjestu primjene.
U vrlo rijetkim slučajevima na mjestu aplikacije može doći do
prolaznog grebanja, eritema (crvenilo
kože), alopecije (gubitak dlake) ili dermatitisa (upala kože) na
mjestu primjene. Ovi učinci
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Activyl 100 mg spot on otopina za jako male pse
Activyl 150 mg spot on otopina za male pse
Activyl 300 mg spot on otopina za srednje pse
Avtivyl 600 mg spot on otopina za velike pse
Activyl 900 mg spot on otopina za iznimno velike pse
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
DJELATNE TVARI:
Jedan ml sadržava 195 mg indoksakarba.
Jedna pipeta s jediničnom dozom sadrži:
DOZA (ML)
INDOKSAKARB (MG)
Activyl za jako male pse (1,5 - 6,5 kg)
0,51
100
Activyl za male pse (6,6 - 10 kg)
0,77
150
Activyl za srednje pse (10,1 - 20 kg)
1,54
300
Avtivyl za velike pse (20,1 – 40 kg)
3,08
600
Activyl za iznimno velike pse (40,1 - 60 kg)
4,62
900
POMOĆNE TVARI
:
Izopropilni alkohol 354 mg/ml.
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Spot-on otopina.
Bistra, bezbojna do žuta otopina.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Psi.
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Liječenje i sprečavanje infestacije buhama (
_Ctenocephalides felis_
).Učinkovitost protiv novih
infestacija buhama traje 4 tjedna nakon jedne aplikacije.
Ubija razvojne stadije buha koje se nalaze i u neposrednoj blizini
ljubimca tretiranog Activylom.
4.3
KONTRAINDIKACIJE
Nema.
4.4
POSEBNA UPOZORENJA ZA SVAKU OD CILJNIH VRSTA ŽIVOTINJA
3
Nema.
4.5
POSEBNE MJERE PREDOSTROŽNOST ZA PRIMJENU
Posebne mjere predostrožnost za primjenu na životinjama
Proizvod ne treba primjenjivati kod pasa mlađih od 8 tjedana starosti
jer kod takvih pasa nije utvrđena
neškodljivost.
Proizvod ne treba primjenjivati kod pasa koji imaju manje od 1,5 kg
jer kod takvih pasa nije utvrđena
neškodljivost.
Osigurati da doza (pipeta) odgovara težini tretiranog psa (vidjeti
odjeljak 4.9)
Aplicirati proizvod na netaknutu površinu kože. Aplicirati na mjesto
na kojem se pas ne može lizati
kao što je opisano u odjeljku 4.9. Osigurati da životinje međusobno
ne dolaze u kontakt odmah nakon
tretmana. Tretirane životinje treba držati odvoj
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 05-04-2019
Summary of Product characteristics Summary of Product characteristics Bulgarian 05-04-2019
Public Assessment Report Public Assessment Report Bulgarian 28-02-2011
Patient Information leaflet Patient Information leaflet Spanish 05-04-2019
Public Assessment Report Public Assessment Report Spanish 28-02-2011
Patient Information leaflet Patient Information leaflet Czech 05-04-2019
Public Assessment Report Public Assessment Report Czech 28-02-2011
Patient Information leaflet Patient Information leaflet Danish 05-04-2019
Public Assessment Report Public Assessment Report Danish 28-02-2011
Patient Information leaflet Patient Information leaflet German 05-04-2019
Public Assessment Report Public Assessment Report German 28-02-2011
Patient Information leaflet Patient Information leaflet Estonian 05-04-2019
Public Assessment Report Public Assessment Report Estonian 28-02-2011
Patient Information leaflet Patient Information leaflet Greek 05-04-2019
Public Assessment Report Public Assessment Report Greek 28-02-2011
Patient Information leaflet Patient Information leaflet English 05-04-2019
Public Assessment Report Public Assessment Report English 28-02-2011
Patient Information leaflet Patient Information leaflet French 05-04-2019
Public Assessment Report Public Assessment Report French 28-02-2011
Patient Information leaflet Patient Information leaflet Italian 05-04-2019
Public Assessment Report Public Assessment Report Italian 28-02-2011
Patient Information leaflet Patient Information leaflet Latvian 05-04-2019
Public Assessment Report Public Assessment Report Latvian 28-02-2011
Patient Information leaflet Patient Information leaflet Lithuanian 05-04-2019
Summary of Product characteristics Summary of Product characteristics Lithuanian 05-04-2019
Public Assessment Report Public Assessment Report Lithuanian 28-02-2011
Patient Information leaflet Patient Information leaflet Hungarian 05-04-2019
Summary of Product characteristics Summary of Product characteristics Hungarian 05-04-2019
Public Assessment Report Public Assessment Report Hungarian 28-02-2011
Patient Information leaflet Patient Information leaflet Maltese 05-04-2019
Public Assessment Report Public Assessment Report Maltese 28-02-2011
Patient Information leaflet Patient Information leaflet Dutch 05-04-2019
Public Assessment Report Public Assessment Report Dutch 28-02-2011
Patient Information leaflet Patient Information leaflet Polish 05-04-2019
Public Assessment Report Public Assessment Report Polish 28-02-2011
Patient Information leaflet Patient Information leaflet Portuguese 05-04-2019
Summary of Product characteristics Summary of Product characteristics Portuguese 05-04-2019
Public Assessment Report Public Assessment Report Portuguese 28-02-2011
Patient Information leaflet Patient Information leaflet Romanian 05-04-2019
Public Assessment Report Public Assessment Report Romanian 28-02-2011
Patient Information leaflet Patient Information leaflet Slovak 05-04-2019
Public Assessment Report Public Assessment Report Slovak 28-02-2011
Patient Information leaflet Patient Information leaflet Slovenian 05-04-2019
Summary of Product characteristics Summary of Product characteristics Slovenian 05-04-2019
Public Assessment Report Public Assessment Report Slovenian 28-02-2011
Patient Information leaflet Patient Information leaflet Finnish 05-04-2019
Public Assessment Report Public Assessment Report Finnish 28-02-2011
Patient Information leaflet Patient Information leaflet Swedish 05-04-2019
Public Assessment Report Public Assessment Report Swedish 28-02-2011
Patient Information leaflet Patient Information leaflet Norwegian 05-04-2019
Summary of Product characteristics Summary of Product characteristics Norwegian 05-04-2019
Patient Information leaflet Patient Information leaflet Icelandic 05-04-2019
Summary of Product characteristics Summary of Product characteristics Icelandic 05-04-2019

Search alerts related to this product

View documents history